This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Health Winners & Losers

Noven shares rose $1.24, or 9.2%, to $14.75.

Wednesday after close, Somaxon Pharmaceuticals (SOMX) reported a net loss of $5.7 million, or 31 cents a share, vs. $9.8 million, or 55 cents a share, for the year-ago quarter. Analysts were expecting a loss closer to 39 cents a share for the quarter, and JP Morgan upgraded the stock to neutral from underweight on Thursday. Shares garnered 89 cents, or 15.5%, to $6.65.

Less fortunate Thursday was Abraxis BioScience (ABBI), which reported adjusted third-quarter earnings of $23.1 million, or 15 cents a share, in the recent quarter, compared to $16.7 million, or 10 cents a share, in the year-ago period. And the company reported revenue of $241 million, vs. $203.1 million in the 2006 quarter, falling shy of estimates of analysts surveyed by Thomson Financial who expected 22 cents a share, on revenue of $253.9 million. Shares fell $2.29, or 9.5%, to $21.93.

Also, Corcept (CORT - Get Report) gave up 49 cents, or 15.2%, to $2.75. The company reported a third-quarter loss of $3.4 million, or 9 cents a share, vs. a loss of $6.4 million, or 28 cents a share, in the year-ago period. The consensus target was for a loss of 9 cents a share.

And hitting a new 52-week low, BioCryst (BCRX - Get Report) aired its results as well. The company reported revenue of $20.5 million vs. $1.8 million in the year-ago quarter, and a net loss of $11 million, or 32 cents a share, compared to a loss of $15.6 million, or 53 cents a share, in the year-ago quarter. The consensus target was a loss of 28 cents a share on revenue of $10.51 million. Shares declined 72 cents, or 9.4%, to $6.95.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BIB $39.77 -5.60%
BCRX $3.00 -7.40%
CORT $4.81 -0.41%
FOLD $6.88 -2.80%
AAPL $94.26 -0.97%


Chart of I:DJI
DOW 17,668.69 -82.22 -0.46%
S&P 500 2,051.97 -11.40 -0.55%
NASDAQ 4,728.9080 -34.3160 -0.72%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs